Adaptive deep brain stimulation for dynamic gait control in Parkinson’s disease: a randomized feasibility trial
Адаптивная глубокая стимуляция мозга для динамического контроля походки при болезни Паркинсона: рандомизированное исследование целесообразности
2026-06-15
SCID: 54.1/55cuucr9
Discuss with AI
adaptive deep brain stimulationgait-phase biomarkersgait-synchronized stimulationpallidal DBSrandomized crossover trial
Figures from the paper
Abstract (AI)
A randomized crossover study of five patients with Parkinson's disease (PD) demonstrates that gait-synchronized adaptive deep brain stimulation is feasible and safe, and reduces falls compared with continuous stimulation. Gait dysfunction in PD is a major source of disability and is often insufficiently treated by continuous deep brain stimulation (cDBS). Although adaptive DBS (aDBS) has shown efficacy for other motor symptoms using β-based, state-driven neural signals, gait is a dynamic, cyclical behavior that may require temporally precise modulation. Here we evaluated a behavior-contingent aDBS approach that synchronizes stimulation to gait phase. We reported a single-center, blinded, randomized, crossover study evaluating the feasibility of identifying patient-specific biomarkers to drive aDBS. The primary outcome was feasibility of successful identification of gait-phase biomarkers to implement aDBS. Five participants with PD undergoing pallidal DBS and subdural electrode paddle implantation were enrolled. We successfully identified personalized gait-phase biomarkers from cortical or pallidal field potentials in all five patients and embedded them into a bidirectional neurostimulator. During acute in-clinic testing, aDBS improved step variability and step symmetry versus cDBS. Three participants subsequently completed a double-blinded, multi-day crossover phase. In this setting, aDBS maintained general motor symptom control, reduced falls and yielded patient-specific gait improvements. No adverse events occurred and aDBS was well tolerated. These findings establish the feasibility of biomarker-driven, movement-synchronized neuromodulation and support the development of a larger randomized trial to determine clinical efficacy. ClinicalTrial.gov registration: NCT04675398 .
Key Findings
1
During acute in-clinic testing, aDBS improved step variability and step symmetry compared with continuous DBS (cDBS).
2
Gait-synchronized adaptive deep brain stimulation (aDBS) is feasible and safe in Parkinson’s disease patients.
3
Identified biomarkers were embedded into a bidirectional neurostimulator to drive gait-phase–synchronized aDBS.
4
In a double-blinded, multi-day crossover phase, aDBS maintained general motor symptom control while reducing falls.
5
Personalized gait-phase biomarkers were successfully identified from cortical or pallidal field potentials in all five participants.
6
Results support feasibility of biomarker-driven, movement-synchronized neuromodulation and justify a larger randomized trial.
7
aDBS yielded patient-specific gait improvements and was well tolerated with no adverse events reported.
Research Object
Gait-synchronized adaptive deep brain stimulation system applied to patients with Parkinson’s disease (pallidal DBS with subdural cortical/pallidal field-potential biomarkers)
Research Subject
Feasibility, safety, and effects on gait control (step variability, step symmetry) and fall reduction when using patient-specific gait-phase biomarkers to drive movement-synchronized aDBS compared with continuous DBS
Publication Details
Publication Date
2026-06-15
Journal
Publisher
ISSN
Cited by
21
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest